Protocol for the Examination of Radical Orchiectomy Specimens From Patients With Malignant Germ Cell and Sex Cord-Stromal Tumors of the Testis

Version: 4.2.0.0
Protocol Posting Date: September 2023
CAP Laboratory Accreditation Program Protocol Required Use Date: June 2024

The changes included in this current protocol version affect accreditation requirements. The new deadline for implementing this protocol version is reflected in the above accreditation date.

For accreditation purposes, this protocol should be used for the following procedures AND tumor types:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Radical Orchiectomy</td>
<td>Includes specimens designated orchietomy and orchidectomy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Germ cell tumors</td>
<td>Includes seminoma and variants, all non-seminomatous germ cell tumors, mixed germ cell tumors</td>
</tr>
<tr>
<td>Malignant sex cord-stromal tumors</td>
<td>Includes Leydig cell tumors, Sertoli cell tumors, granulosa cell tumors, and mixed sex cord tumors</td>
</tr>
</tbody>
</table>

This protocol is NOT required for accreditation purposes for the following:

<table>
<thead>
<tr>
<th>Procedure</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retroperitoneal lymphadenectomy</td>
<td>(consider Testis Retroperitoneal Lymphadenectomy protocol)</td>
</tr>
<tr>
<td>Primary resection specimen with no residual cancer</td>
<td>(e.g., following neoadjuvant therapy)</td>
</tr>
<tr>
<td>Cytologic specimens</td>
<td></td>
</tr>
</tbody>
</table>

The following tumor types should NOT be reported using this protocol:

<table>
<thead>
<tr>
<th>Tumor Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Paratesticular malignancies including appendageal, mesothelial, and soft tissue tumors</td>
<td>(consider Soft Tissue protocol)</td>
</tr>
<tr>
<td>Non-testis germ cell tumors</td>
<td>(consider Extragonadal Germ Cell protocol)</td>
</tr>
<tr>
<td>Lymphoma</td>
<td>(consider the Hodgkin or non-Hodgkin Lymphoma protocols)</td>
</tr>
<tr>
<td>Sarcoma</td>
<td>(consider the Soft Tissue protocol)</td>
</tr>
</tbody>
</table>

Authors
Paari Murugan, MD, FCAP*; Gladell P. Paner, MD, FCAP*; Lara R. Harik, MD, FCAP*; Mahul B. Amin, MD; Daniel Berney, MB; Scott E. Egggener, MD; Muhammad T. Idress, MD; Frank Ingram, MD; Rafael E. Jimenez, MD; Chia Sui Kao, MD; S. Joseph Sirintrapun, MD; Satish K. Tickoo, MD.
With guidance from the CAP Cancer and CAP Pathology Electronic Reporting Committees.
* Denotes primary author.
Accreditation Requirements
This protocol can be utilized for a variety of procedures and tumor types for clinical care purposes. For accreditation purposes, only the definitive primary cancer resection specimen is required to have the core and conditional data elements reported in a synoptic format.

- Core data elements are required in reports to adequately describe appropriate malignancies. For accreditation purposes, essential data elements must be reported in all instances, even if the response is “not applicable” or “cannot be determined.”
- Conditional data elements are only required to be reported if applicable as delineated in the protocol. For instance, the total number of lymph nodes examined must be reported, but only if nodes are present in the specimen.
- Optional data elements are identified with “+” and although not required for CAP accreditation purposes, may be considered for reporting as determined by local practice standards.

The use of this protocol is not required for recurrent tumors or for metastatic tumors that are resected at a different time than the primary tumor. Use of this protocol is also not required for pathology reviews performed at a second institution (i.e., secondary consultation, second opinion, or review of outside case at second institution).

Synoptic Reporting
All core and conditionally required data elements outlined on the surgical case summary from this cancer protocol must be displayed in synoptic report format. Synoptic format is defined as:

- Data element: followed by its answer (response), outline format without the paired Data element: Response format is NOT considered synoptic.
- The data element should be represented in the report as it is listed in the case summary. The response for any data element may be modified from those listed in the case summary, including “Cannot be determined” if appropriate.
- Each diagnostic parameter pair (Data element: Response) is listed on a separate line or in a tabular format to achieve visual separation. The following exceptions are allowed to be listed on one line:
  - Anatomic site or specimen, laterality, and procedure
  - Pathologic Stage Classification (pTNM) elements
  - Negative margins, as long as all negative margins are specifically enumerated where applicable
- The synoptic portion of the report can appear in the diagnosis section of the pathology report, at the end of the report or in a separate section, but all Data element: Responses must be listed together in one location.

Organizations and pathologists may choose to list the required elements in any order, use additional methods in order to enhance or achieve visual separation, or add optional items within the synoptic report. The report may have required elements in a summary format elsewhere in the report IN ADDITION TO but not as replacement for the synoptic report ie, all required elements must be in the synoptic portion of the report in the format defined above.
Summary of Changes
v 4.2.0.0

- WHO 5th Edition update to content and Explanatory Notes
- pTNM Classification update
- LVI question update from "Lymphovascular Invasion" to "Lymphatic and/or Vascular Invasion"
Reporting Template

Protocol Posting Date: September 2023
Select a single response unless otherwise indicated.

CASE SUMMARY: (TESTIS: Radical Orchiectomy)
Standard(s): AJCC-UICC 8

CLINICAL

+Pre-Orchiectomy Serum Tumor Marker(s) (Note A) (select all that apply)
  ___ Unknown: _________________
  ___ Serum marker studies within normal limits
  ___ Alpha-fetoprotein (AFP) elevation
  ___ Beta-subunit of human chorionic gonadotropin (b-hCG) elevation
  ___ Lactate dehydrogenase (LDH) elevation
  ___ Other (specify): _________________

+Post-Orchiectomy Serum Tumor Marker(s) (Note A) (select all that apply)
  ___ Unknown: _________________
  ___ Serum marker studies within normal limits
  ___ Alpha-fetoprotein (AFP) elevation
  ___ Beta-subunit of human chorionic gonadotropin (b-hCG) elevation
  ___ Lactate dehydrogenase (LDH) elevation
  ___ Other (specify): _________________

+Serum Tumor Markers (S) (applies to post-orchiectomy values) (Note A)
  ___ SX (serum marker studies not available or performed)
  ___ S0 (serum marker study levels within normal limits)
  ___ S1 (less than 1.5 x the upper limit of normal for the LDH assay, and HCG less than 5,000 mIU / mL, and AFP less than 1,000 ng / mL)
  ___ S2 (1.5-10 x the upper limit of normal for the LDH assay, or HCG 5,000-50,000 mIU / mL, or AFP 1,000-10,000 ng / mL)
  ___ S3 (greater than 10 x the upper limit of normal for the LDH assay, or HCG greater than 50,000 mIU / mL, or AFP greater than 10,000 ng / mL)

SPECIMEN

Specimen Laterality
  ___ Right
  ___ Left
  ___ Not specified

TUMOR

Tumor Focality
  ___ Unifocal
  ___ Multifocal
  ___ Cannot be determined: _________________
Tumor Size
___ Greatest dimension of main tumor mass in Centimeters (cm): _________________ cm
+Additional Dimension of Main Tumor Mass in Centimeters (cm): ____ x ____ cm
___ Cannot be determined (explain): ____________________________

Additional Tumor Nodule(s) (may repeat for each nodule)  
Greatest Dimension of Additional Tumor Nodule in Centimeters (cm)
___ Not applicable
___ Specify in Centimeters (cm): _________________ cm
___ Cannot be determined (explain): ____________________________

Histologic Type (Notes B,C,D) (select all that apply)

Germ cell tumors derived from germ cell neoplasia in situ
Non-invasive germ cell neoplasia
___ Germ cell neoplasia in situ (GCNIS)
___ Other intratubular germ cell tumor (specify): ____________________________
___ Gonadoblastoma
The germinoma family of tumors
___ Seminoma
___ Seminoma with syncytiotrophoblastic cells
Non-seminomatous germ cell tumors
___ Embryonal carcinoma
___ Yolk sac tumor, postpubertal-type
___ Choriocarcinoma
___ Non-choriocarcinomatous trophoblastic tumor, NOS
___ Placental site trophoblastic tumor
___ Epithelioid trophoblastic tumor
___ Cystic trophoblastic tumor
___ Teratoma, postpubertal-type
___ Teratoma with somatic-type malignancy
  Select all that apply
    ___ Adenocarcinoma
    ___ Embryonic-type neuroectodermal tumor
    ___ Rhabdomyosarcoma
    ___ Other (specify): ____________________________

Mixed germ cell tumors
___ Mixed germ cell tumor
  Select all that apply
    ___ Seminoma (specify percentage): _________________ %
    ___ Embryonal carcinoma (specify percentage): _________________ %
    ___ Yolk sac tumor, postpubertal-type (specify percentage): _________________ %
    ___ Choriocarcinoma (specify percentage): _________________ %
    ___ Teratoma (specify percentage): _________________ %
    ___ Other (specify type and percentage): ____________________________

Germ cell tumors of unknown type
___ Scar diagnostic of regressed germ cell tumor
___ Scar suspicious for regressed germ cell tumor

Germ cell tumors unrelated to germ cell neoplasia in situ
___ Spermatocytic tumor
___ Spermatocytic tumor with a sarcomatous component
___ Testicular neuroendocrine tumor, prepubertal-type
___ Mixed teratoma and yolk sac tumor, prepubertal-type
___ Yolk sac tumor, prepubertal-type
Malignant sex cord-stromal tumors

___ Leydig cell tumor
___ Sertoli cell tumor, NOS
___ Sertoli cell tumor, large cell calcifying
___ Sertoli cell tumor, intratubular large cell hyalinizing
___ Granulosa cell tumor, adult type
___ Sex cord-stromal tumor, mixed type (specify components and approximate percentages):

___ Sex cord-stromal tumor type, unclassified
___ Other histologic type not listed (specify): _________________
___ Cannot be determined: _________________

+Histologic Type Comment: _________________

Tumor Extent (Note E) (select all that apply)

___ Germ cell neoplasia in situ only
___ Limited to testis
# See Note E for definition of rete testis invasion
___ Invades rete testis#
___ Invades hilar soft tissue
___ Invades epididymis
___ Invades through tunica albuginea and perforates tunica vaginalis (mesothelial layer)
___ Invades spermatic cord
___ Invades scrotum
___ Invades other structures (specify): _________________
___ Cannot be determined: _________________
___ No evidence of primary tumor

Lymphatic and / or Vascular Invasion (Note F)

___ Not identified
___ Present
___ Cannot be determined: _________________

+Tumor Comment: _________________

MARGINS

Margin Status

___ All margins negative for tumor
___ Tumor present at margin

Margin(s) Involved by Tumor (select all that apply)

___ Spermatic cord
___ Other (specify): _________________
___ Cannot be determined (explain): _________________
___ Other (specify): _________________
___ Cannot be determined (explain): _________________
___ Not applicable

+Margin Comment: _________________
REGIONAL LYMPH NODES

Regional Lymph Node Status
___ Not applicable (no regional lymph nodes submitted or found)
___ Regional lymph nodes present
   ___ All regional lymph nodes negative for tumor
   ___ Tumor present in regional lymph node(s)

Number of Lymph Nodes with Tumor
___ Exact number (specify): __________________
___ At least (specify): __________________
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

Nodal Site(s) with Tumor (required only if applicable) (select all that apply)
___ Not applicable
   ___ Interaortocaval: __________________
   ___ Paraaortic: __________________
   ___ Paracaval: __________________
   ___ Preaortic: __________________
   ___ Precaval: __________________
   ___ Retroaortic: __________________
   ___ Retrocaval: __________________
   ___ Other (specify): __________________
   ___ Cannot be determined: __________________

+ Size of Largest Nodal Metastatic Deposit
  Specify in Centimeters (cm)
___ Exact size: __________________ cm
___ At least (specify): __________________ cm
___ Greater than: __________________ cm
___ Less than: __________________ cm
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

+Nodal Site with Largest Metastatic Deposit (select all that apply)
___ Interaortocaval: __________________
___ Paraaortic: __________________
___ Paracaval: __________________
___ Preaortic: __________________
___ Precaval: __________________
___ Retroaortic: __________________
___ Retrocaval: __________________
___ Other (specify): __________________
___ Cannot be determined: __________________

Size of Largest Lymph Node or Nodal Mass with Tumor
Specify in Centimeters (cm)
___ Exact size: __________________ cm
___ At least (specify): __________________ cm
___ Greater than: __________________ cm
___ Less than: __________________ cm
___ Other (specify): __________________
___ Cannot be determined (explain): __________________

+ Largest Lymph Node with Tumor (specify site): __________________
Extranodal Extension
___ Not identified
___ Present
___ Cannot be determined: ____________________

Histologic Subtype of Germ Cell Tumor in Involved Lymph Node(s) (required only if applicable) (select all that apply)
___ Not applicable
___ Seminoma (specify percent): _______________ %
___ Seminoma with syncytiotrophoblastic cells (specify percent): _______________ %
___ Embryonal carcinoma (specify percent): _______________ %
___ Yolk sac tumor, postpubertal-type (specify percent): _______________ %
___ Choriocarcinoma (specify percent): _______________ %
___ Placental site trophoblastic tumor (specify percent): _______________ %
___ Epithelioid trophoblastic tumor (specify percent): _______________ %
___ Cystic trophoblastic tumor (specify percent): _______________ %
___ Teratoma, postpubertal-type (specify percent): _______________ %
___ Teratoma with somatic-type malignancy
Select all that apply
___ Adenocarcinoma
___ Embryonic-type neuroectodermal tumor
___ Rhabdomyosarcoma
___ Other (specify): ____________________
___ Spermatocytic tumor
___ Spermatocytic tumor with a sarcomatous component
___ Yolk sac tumor, prepubertal-type
___ Leydig cell tumor
___ Sertoli cell tumor
___ Sertoli cell tumor, large cell calcifying
___ Granulosa cell tumor, adult type
___ Sex cord-stromal tumor type, mixed
___ Sex cord-stromal tumor type, unclassified
___ Other histologic type not listed (specify): ____________________
___ Other (specify): ____________________
___ Cannot be determined (explain): ____________________

Number of Lymph Nodes Examined
___ Exact number (specify): ____________________
___ At least (specify): ____________________
___ Other (specify): ____________________
___ Cannot be determined (explain): ____________________

+Regional Lymph Node Comment: ____________________

DISTANT METASTASIS

Distant Site(s) Involved, if applicable (select all that apply)
___ Not applicable
___ Non-retroperitoneal lymph node(s): ____________________
___ Lung: ____________________
___ Other organ(s) or site(s) (specify): ____________________
___ Cannot be determined: ____________________
pTNM CLASSIFICATION (AJCC 8th Edition) (Note G)
Reporting of pT, pN, and (when applicable) pM categories is based on information available to the pathologist at the time the report is issued. As per the AJCC (Chapter 1, 8th Ed.) it is the managing physician’s responsibility to establish the final pathologic stage based upon all pertinent information, including but potentially not limited to this pathology report.

Modified Classification (required only if applicable) (select all that apply)
___ Not applicable
___ y (post-neoadjuvant therapy)
___ r (recurrence)

pT Category
___ pT not assigned (cannot be determined based on available pathological information)
___ pT0: No evidence of primary tumor
___ pTis: Germ cell neoplasia *in situ*
___ pT1: Tumor limited to testis (including rete testis invasion) without lymphovascular invasion
# Subclassification of pT1 applies only to pure seminoma.
   ___ pT1a: Tumor smaller than 3 cm in size#
   ___ pT1b: Tumor 3 cm or larger in size#
   ___ pT1 (subcategory cannot be determined)
___ pT2: Tumor limited to testis (including rete testis invasion) with lymphovascular invasion, or tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion
___ pT3: Tumor directly invades spermatic cord soft tissue with or without lymphovascular invasion
___ pT4: Tumor invades scrotum with or without lymphovascular invasion

T Suffix (required only if applicable)
___ Not applicable
___ (m) multiple primary synchronous tumors in a single organ

pN Category
___ pN not assigned (no nodes submitted or found)
___ pN not assigned (cannot be determined based on available pathological information)
___ pN0: No regional lymph node metastasis
___ pN1: Metastasis with a lymph node mass 2 cm or smaller in greatest dimension, and less than or equal to five nodes positive, none larger than 2 cm in greatest dimension
___ pN2: Metastasis with a lymph node mass larger than 2 cm but not larger than 5 cm in greatest dimension, or more than five nodes positive, none larger than 5 cm; or evidence of extranodal extension of tumor
___ pN3: Metastasis with a lymph node mass larger than 5 cm in greatest dimension

pM Category (required only if confirmed pathologically)
___ Not applicable - pM cannot be determined from the submitted specimen(s)
___ pM1: Distant metastasis
   ___ pM1a: Non-retroperitoneal nodal or pulmonary metastases
   ___ pM1b: Non-pulmonary visceral metastases
   ___ pM1 (subcategory cannot be determined)

ADDITIONAL FINDINGS (Note H)

+Additional Findings (select all that apply)
___ None identified
___ Germ cell neoplasia in situ (GCNIS)
___ Microlith
___ Sertoli cell nodule (Pick’s adenoma)
___ Atrophy
___ Other (specify): ____________________

COMMENTS

Comment(s): ____________________
**Explanatory Notes**

**A. Serum Markers**
The protocol emphasizes the importance of relevant clinical information in the pathologic evaluation of specimens. Serum marker studies play a key role in the clinical management of patients with testicular germ cell tumors. The occurrence of elevated serum levels of alpha-fetoprotein (AFP) or the beta subunit of human chorionic gonadotropin (b-hCG) may indicate the need for additional sections of certain specimens if the initial findings do not account for such elevations. Information regarding postorchiectomy serum marker status (lactate dehydrogenase [LDH], AFP, and b-hCG) is also important in the “S” categorization of the tumor for stage groupings. Postorchiectomy serum markers are important for the assignment of stage IS.

The serum tumor markers (S) category comprises the following:
- Alpha fetoprotein (AFP) – half-life 5 to 7 days
- Human chorionic gonadotropin (hCG) – half-life 1 to 3 days
- Lactate dehydrogenase (LDH)

**References**

**B. Tissues Submitted for Microscopic Evaluation**
The entire testicular tumor may be blocked if it requires 10 blocks or less (tissue may be retained for special studies); 10 blocks of larger tumors may be taken, unless the tumor is greater than 10 cm, in which case 1 block may be submitted for every 1 cm of maximum tumor dimension. Blocks must contain the interface with nontumorous testis, as well as the tunica albuginea, even away from the tumor because lymphatic invasion is best appreciated in the peritumoral tissue, as well as in the vessels within and under/parallel to the tunica. When there are multifocal tumors (with greater than or equal to 2 separate tumor nodules), additional tumor nodule(s) should also be sampled. Tissues to be sampled include:
- Tumor, including interface with surrounding testis, and tunica albuginea
- All of the grossly different appearing areas in the tumor
- Testicular hilum/mediastinum testis
- Uninvolved testis, including tunica albuginea
- Epididymis
- Spermatic cord, including cord margin, mid sections and base of cord
- Other lesion(s)
- All identifiable lymph nodes#
- Other tissue(s) submitted with specimen

#For large masses that have obliterated individual nodes, 1 section for every centimeter of maximum tumor dimension, including grossly different looking areas, is recommended.

The margins in a specimen resected for a malignant tumor of the testis, depending on the extent of the surgery, include spermatic cord margin, the parietal layer of tunica vaginalis, and scrotal skin.
C. Histologic Type
The protocol mainly applies to malignant tumors of the testis, the vast majority of which are of germ cell origin. It may also be applied to other malignant or potentially malignant sex cord stromal tumors of the testis included in the classification below. While the presence of metastasis is the most definitive indicator of malignancy in the sex cord stromal tumors, evaluation of features associated with higher risk of malignant behavior, including large tumor size, infiltrative margins, tumor necrosis, increased mitotic activity, nuclear atypia and lymphovascular invasion is recommended. For hematolymphoid neoplasms involving the testis, refer to the corresponding CAP protocols.

2022 WHO Classification of Testicular Tumors

Germ cell tumors derived from germ cell neoplasia in situ
Non-invasive germ cell neoplasia
  Germ cell neoplasia in situ
  Specific forms of intratubular germ cell neoplasia
  Gonadoblastoma
The germinoma family of tumors
  Seminoma
Non-seminomatous germ cell tumors
  Embryonal carcinoma
  Yolk sac tumor, postpubertal-type
  Choriocarcinoma
  Placental site trophoblastic tumor
  Epithelioid trophoblastic tumor
  Cystic trophoblastic tumor
  Teratoma, postpubertal-type
  Teratoma with somatic-type malignancy
Mixed germ cell tumors of the testis
  Mixed germ cell tumors
Germ cell tumors of unknown type
  Regressed germ cell tumors
Germ cell tumors unrelated to germ cell neoplasia in situ
  Spermatocytic tumor
  Yolk sac tumor, prepubertal-type
  Testicular neuroendocrine tumor, prepubertal-type
  Mixed teratoma and yolk sac tumor, prepubertal-type
Sex cord-stromal tumors of the testis
Leydig cell tumor
  Leydig cell tumor
Sertoli cell tumors
  Sertoli cell tumor
  Large cell calcifying Sertoli cell tumor
Granulosa cell tumors
  Adult granulosa cell tumor
Mixed and other sex cord-stromal tumors
  Mixed sex cord-stromal tumor
  Sex cord stromal tumor NOS
References


D. Scar

Testicular scars, particularly in patients presenting with metastatic disease and clinically inapparent testicular primaries, may represent regressed, "burnt-out" testicular germ cell tumors. There are 2 established criteria to indicate a scar is diagnostic of a regressed germ cell tumor (GCT): a scar with associated germ cell neoplasia in situ (GCNIS) or a scar that contains coarse intratubular calcifications within expanded tubular profiles, which correspond to dystrophic calcifications that occurred in completely necrotic intratubular embryonal carcinoma. Features that are suspicious for, although not diagnostic of, regressed germ cell tumors include testicular atrophy, microlithiasis, and, in the scar, lymphoplasmacytic infiltrates and prominent vascularity. In otherwise pure seminoma, such partial regression may have clinically important implications, since it is possible that some of these scars may represent regression of a nonseminomatous germ cell tumor component of the tumor.

References


E. Invasion of the Rete Testis, Hilar/Mediastinal Soft Tissue, Epididymis or Tunica Vaginalis

Tumors invading the tunica vaginalis (perforating the mesothelial lining) (Figure 4, Tumor A) are considered category pT2 by the American Joint Committee on Cancer (AJCC) TNM staging system. Invasion of rete testis is not assigned a higher pT category than that for a tumor limited to the testis. Rete testis invasion has been reported by some to be associated with higher risk of relapse in clinical stage I seminoma. Rete testis invasion is that the invasive tumor involves the rete testis stroma, with or without luminal involvement. Pagetoid extension of GCNIS into the rete testis should not be considered rete testis invasion. Hilar soft tissue invasion (Figure 4, Tumor B) is the predominant pathway of extratesticular extension for testicular tumors. There is evidence beginning to accumulate that rete testis and hilar soft tissue invasion have predictive value for metastatic disease in patients with nonseminomatous GCTs. Invasion of epididymis and hilar soft tissue is staged as pT2 by the 8th edition of AJCC TNM.
Figure 4. Diagrammatic representation of a tumor (Tumor A) invading tunica vaginalis, perforating through the mesothelium, and another tumor (Tumor B) partly involving the rete testis and invading the hilar soft tissue. Figure courtesy of Satish K. Tickoo, MD.

References

F. Lymphatic and/or Vascular Invasion
In several studies, the presence of vascular space invasion (usually lymphatic but possibly also capillary or venous invasion) has been correlated with a significantly elevated risk for distant metastasis. This observation, therefore, is most pertinent for patients who have clinical stage I disease, i.e., those who have no evidence of spread beyond the testis by clinical examination (including radiographic and serum marker studies). Some clinicians manage the patients with clinical stage I disease who lack evidence of lymphatic or vascular invasion in their orchiectomy specimens (with possibly other favorable prognostic features, such as relatively small amounts of embryonal carcinoma) by close follow-up examinations rather than intervention.

According to the 8th edition AJCC TNM staging system, discontinuous involvement of the spermatic cord soft tissue via a vascular thrombus is better regarded as a metastatic deposit (pM1), a change from the previous edition where this finding was regarded as pT3, similar to direct tumor extension into the spermatic cord. The AJCC acknowledges that the level of evidence to support this change is limited (Level III). While a subsequent retrospective analysis found no statistically significant difference in terms of clinical stage at presentation and the likelihood of recurrence between the two groups, a more recent retrospective multi-institutional study observed discontinuous involvement of the spermatic cord soft tissue via vascular thrombus was significantly associated with advanced clinical stage at presentation compared to continuous cord involvement. Presence of only an intravascular tumor in the spermatic cord in the absence of parenchymal invasion is considered pT2.
References


G. Staging

The protocol recommends staging according to the AJCC TNM staging system (Figures 1, 2 and 3). Additional criteria for staging seminomas according to a modification of the Royal Marsden system are also recommended. Some studies suggest that the staging of patients with seminoma by the TNM system is less meaningful therapeutically than staging by a modification of the Royal Marsden method. Also, the data from a large Danish study of seminomas clinically limited to the testis do not support the conclusion that local staging of the primary tumor, as performed in the TNM system, provides useful prognostic information; rather, the most valuable prognostic indicator was the size of the seminoma. This protocol therefore encourages the use of the TNM system with optional use of the modified Royal Marsden staging system for patients with seminoma.

Figure 2. pT2 is defined as tumor limited to testis (including rete testis invasion) with lymphovascular invasion, or tumor invading hilar soft tissue or epididymis or penetrating visceral mesothelial layer covering the external surface of tunica albuginea with or without lymphovascular invasion. From: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. Reproduced with permission.

Figure 3. pT3 is defined as tumor invading the spermatic cord and pT4 is defined as tumor invading the scrotum. From: Amin MB, Edge SB, Greene FL, et al, eds. AJCC Cancer Staging Manual. 8th ed. New York, NY: Springer; 2017. Reproduced with permission.

AJCC TNM and Stage Groupings
By AJCC convention, the designation “T” refers to a primary tumor that has not been previously treated. The symbol “p” refers to the pathologic classification of the TNM, as opposed to the clinical classification, and is based on gross and microscopic examination. pT entails a resection of the primary tumor or biopsy adequate to evaluate the highest pT category, pN entails removal of nodes adequate to validate lymph node metastasis, and pM implies microscopic examination of distant lesions. Clinical classification (cTNM) is usually carried out by the referring physician before treatment during initial evaluation of the patient or when pathologic classification is not possible.
Pathologic staging is usually performed after surgical resection of the primary tumor. Pathologic staging depends on pathologic documentation of the anatomic extent of disease, whether or not the primary tumor has been completely removed. If a biopsied tumor is not resected for any reason (e.g., when technically unfeasible) and if the highest T and N categories or the M1 category of the tumor can be confirmed microscopically, the criteria for pathologic classification and staging have been satisfied without total removal of the primary cancer.

**TNM Descriptors**

For identification of special cases of TNM or pTNM classifications, the “m” suffix and “y,” “r,” and “a” prefixes are used. Although they do not affect the stage grouping, they indicate cases needing separate analysis.

The “m” suffix indicates the presence of multiple primary tumors in a single site and is recorded in parentheses: pT(m)NM.

The “y” prefix indicates those cases in which classification is performed during or following initial multimodality therapy (i.e., neoadjuvant chemotherapy, radiation therapy, or both chemotherapy and radiation therapy). The cTNM or pTNM category is identified by a “y” prefix. The ycTNM or ypTNM categorizes the extent of tumor actually present at the time of that examination. The “y” categorization is not an estimate of tumor prior to multimodality therapy (i.e., before initiation of neoadjuvant therapy).

The “r” prefix indicates a recurrent tumor when staged after a documented disease-free interval and is identified by the “r” prefix: rTNM.

**References**


**H. Additional Findings**

Important findings include Leydig cell hyperplasia, which may be correlated with β-hCG elevation; scarring, the presence of hemosiderin-laden macrophages, and coarse intratubular calcifications in expanded tubular profiles (distinct from microlithiasis), which may indicate regression of a tumor; testicular atrophy; sertoli cell nodules (Pick’s adenoma), which most often are associated with undescended testes, and abnormal testicular development (e.g., dysgenesis or androgen-insensitivity syndrome).1,2

**References**